André Mercanzini, PhD, is a founder and chief technology officer of Aleva Neurotherapeutics SA (Lausanne, Switzerland). He has held R&D positions at the Institute for Biomedical Engineering, University of Toronto; the Artificial Intelligence Laboratory, Massachusetts Institute of Technology; Bosch Research in Silicon Valley, CA; Sensimed AG in Lausanne, Switzerland; and at Zyvex Corporation in Dallas, Texas, the first startup company to commercialize nanotechnology.

He received his BS in engineering physics from the University of Toronto in 2003 and his PhD from the Swiss Federal Institute of Technology, Lausanne (EPFL) in 2009. His doctoral research involved the development of microfabrication processes for implantable neurostimulation and recording devices. He holds two issued US patents on microassembly and four issued patent families on neurostimulation devices.